For a 74‑year‑old patient with COPD on BiPAP who has severe anxiety and depression and is currently taking alprazolam 0.25 mg three times daily as needed, hydroxyzine 25 mg three times daily as needed, sertraline 25 mg three times daily, and mirtazapine 15 mg daily, how should the medication regimen be simplified and optimized?

Medication Optimization for COPD with Severe Anxiety/Depression

Discontinue alprazolam immediately and consolidate to mirtazapine monotherapy at bedtime, as benzodiazepines are contraindicated in COPD patients on BiPAP due to respiratory depression risk, and the current polypharmacy regimen is unnecessarily complex and potentially dangerous.

Critical Safety Issue: Benzodiazepines in COPD

Avoid sedatives and hypnotics in COPD patients, particularly those with severe disease requiring BiPAP 1. The European Respiratory Society explicitly states to "avoid sedatives and hypnotics" in COPD management 1. Alprazolam poses significant risks:

• Respiratory depression in a patient already requiring BiPAP support
• Loss of alertness is a critical parameter in severe COPD exacerbations 1
• Paradoxical effects including agitation, irritability, and cognitive impairment 2
• High dependence potential with withdrawal seizures upon discontinuation 2

Recommended Simplified Regimen

Primary Antidepressant: Mirtazapine

Increase mirtazapine to 30 mg PO at bedtime (currently underdosed at 15 mg) 3, 4:

• Dual benefit: Treats both depression AND anxiety effectively 4
• Sedating properties address sleep disturbances without respiratory depression risk
• Superior to SSRIs for anxiety symptoms in depression (SMD = -0.16, p < 0.01) 4
• Well-tolerated with comparable acceptability to placebo 4
• Dose can be titrated up to 45 mg if needed after 1-2 weeks 3

Discontinue Redundant Medications

Eliminate sertraline 25 mg TID (assuming this is what "seroqule" refers to, as the dose/frequency matches sertraline more than quetiapine):

• Mirtazapine provides superior anxiolytic effects 4
• Sertraline requires 50 mg daily minimum for therapeutic effect 5
• Current TID dosing is non-standard and subtherapeutic
• If this is actually quetiapine 25 mg TID (75 mg/day), still discontinue—this is a subtherapeutic antipsychotic dose with metabolic risks and no clear indication

Taper and discontinue alprazolam 0.25 mg TID:

• Reduce by 0.25 mg every 3 days to prevent withdrawal seizures 2
• Mirtazapine's anxiolytic effects will replace benzodiazepine function safely

Discontinue hydroxyzine 25 mg TID PRN:

• Anticholinergic burden in elderly COPD patient
• Redundant once mirtazapine is optimized
• No evidence supporting antihistamines for anxiety in COPD

Evidence-Based Rationale

Why Mirtazapine is Optimal for This Patient

1. Anxiety efficacy: Parallels SSRIs and benzodiazepines in GAD without respiratory risks 4
2. Depression treatment: Effective for MDD with prominent anxiety features 4
3. COPD compatibility: No respiratory depression, unlike benzodiazepines 1
4. Sleep improvement: Sedating properties beneficial for COPD-related sleep disturbances 4
5. Appetite stimulation: May benefit if patient has low BMI (common COPD comorbidity) 6

Non-Pharmacological Interventions (Essential Adjuncts)

While not requested, these are critical for outcomes 7, 6:

• Pulmonary rehabilitation: Reduces anxiety/depression in COPD (meta-analysis evidence) 7
• Supervised exercise with stress management: Specific benefit for anxiety/depression in COPD 7
• Cognitive-behavioral therapy: Clear benefits demonstrated 6

Implementation Algorithm

Week 1-2:

• Start mirtazapine 30 mg qHS
• Begin alprazolam taper (reduce by 0.25 mg every 3 days)
• Continue sertraline/quetiapine temporarily

Week 3-4:

• Alprazolam should be discontinued by now
• Discontinue sertraline/quetiapine
• Discontinue hydroxyzine PRN
• Continue mirtazapine 30 mg qHS alone

Week 6-8:

• Assess response using HADS or HAMD-17 8, 9
• If inadequate response, increase mirtazapine to 45 mg qHS 3
• Monitor for sedation, weight gain

Critical Monitoring

• Respiratory status: Ensure BiPAP compliance, monitor for CO2 retention
• Withdrawal symptoms: During alprazolam taper (anxiety, seizures, insomnia) 2
• Depression/anxiety scores: Use validated tools (HADS, HAMD-17) 8, 9
• Functional capacity: 6-minute walk distance improves with depression treatment 8

Common Pitfalls to Avoid

1. Continuing benzodiazepines in severe COPD—absolute contraindication with BiPAP 1
2. Polypharmacy without clear benefit—current regimen has 4 psychotropic agents with overlapping mechanisms
3. Subtherapeutic dosing—mirtazapine 15 mg and sertraline 25 mg TID are both inadequate
4. Abrupt benzodiazepine cessation—requires slow taper to prevent seizures 2
5. Ignoring pulmonary rehabilitation—40% of COPD patients have depression/anxiety; rehabilitation specifically improves both 7

Final regimen: Mirtazapine 30-45 mg PO qHS as monotherapy, with mandatory pulmonary rehabilitation referral.